Crossmark

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Crossref DOI link: https://doi.org/10.1136/jitc-2020-001302

Published Online: 2020-12-21

Published Print: 2020-12

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Pakkala, Suchita

Higgins, Kristin

Chen, Zhengjia

Sica, Gabriel

Steuer, Conor

Zhang, Chao

Zhang, Guojing

Wang, Shuhua

Hossain, Mohammad S

Nazha, Bassel

Beardslee, Tyler

Khuri, Fadlo R

Curran, Walter

Lonial, Sagar

Waller, Edmund K

Ramalingam, Suresh

Owonikoko, Taofeek K https://orcid.org/0000-0002-7724-7728
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02701400 at ClinicalTrials.gov

Documents that mention this clinical trial

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
https://doi.org/10.1136/jitc-2020-001302
Funding

Funding for this research was provided by:

AstraZeneca

National Cancer Institute (P30CA138292)
License Information

License valid from 2020-12-20